THE REGENMED SOLUTION
RegenMed Systems has an exclusive technology license of IP from Stanford and has further developed a minimally invasive Marrow Harvest System (MHS), which in both preclinical and clinical trials has demonstrated its ability to safely and effectively collect more concentrated stem cells than traditional methods while patients are under only local anesthesia.
RegenMed harvest technology is poised to play a critical role in enabling a widening array of therapeutic approaches that utilize marrow derived cells, and can be paired with existing technologies for stem cell processing and site specific delivery.
Owning the critical bone marrow harvest component of many therapeutic approaches provides an opportunity to play a critical role in a number of lucrative, well-established therapies, as well as to partner with others in a growing number of large, emerging markets for regenerative medicine that utilize bone marrow derived cells.
HOW IT WORKS
Following successful development of the initial marrow harvest system (including FDA clearance and CME Mark), RegenMed Systems has now developed the commercial ‘Gen-II’ Marrow Harvest System with a significantly improved FlexShaft, ergononomics, and design for production at scale. The current approach requires multiple painful bone entries and serial aspirates, resulting in diluted marrow and stem cell yield. The RegenMed System is designed to eliminate these shortcomings and (a) includes a rotating flexible shaft (FlexShaft see closeup of tip (b) ) which when powered rotates and moves through the marrow cavity while aspirating stem cell rich marrow. Components include a marrow entry trocar (c) an integrated power source (d) an ergonomic powered handle (e) with speed and aspiration control, and a removable FlexShaft (f).